Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 and multiple ankyrin repeat domains protein 2 (SHANK2) is a postsynaptic scaffold protein and member of the Shank family, primarily localized at the postsynaptic density (PSD) of excitatory synapses in the brain[1][2]. SHANK2 contains ankyrin repeats, SH3, PDZ, proline-rich, and sterile alpha motif (SAM) domains, allowing it to organize large protein-protein interaction complexes and couple membrane receptors, such as NMDA-type and metabotropic glutamate receptors, to the cytoskeleton[1][2][3]. This structural framework is essential for the development, maturation, and function of dendritic spines and synaptic connectivity. Genetic variants in SHANK2 are strongly implicated in autism spectrum disorder, intellectual disability, schizophrenia, and related neurodevelopmental conditions[2][4][5]. While not a typical therapeutic target like a receptor or enzyme, SHANK2 is a key molecular hub in the PSD, and its dysfunction disrupts normal synaptic transmission and neural circuit organization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 and multiple ankyrin repeat domains protein 2 (SHANK2).